Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GB:GSK)
LSE:GSK
Total Valuation
GlaxoSmithKline has a market cap or net worth of £56.24B. The enterprise value is 68.32B.
Market Cap£56.24B
Enterprise Value68.32B
Share Statistics
GlaxoSmithKline has 4,114,156,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,114,156,300
Owned by Insiders1.10%
Owned by Institutions0.08%
Financial Efficiency
GlaxoSmithKline’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee457.18K
Profits Per Employee43.00K
Employee Count68,629
Asset Turnover0.53
Inventory Turnover1.60
Valuation Ratios
The current PE Ratio of GlaxoSmithKline is 21.32. GlaxoSmithKline’s PEG ratio is -0.44.
PE Ratio21.32
PS Ratio1.99
PB Ratio4.02
Price to Fair Value4.02
Price to FCF15.37
Price to Operating Cash Flow8.38
PEG Ratio-0.44
Income Statement
In the last 12 months, GlaxoSmithKline had revenue of 31.38B and earned 2.58B in profits. Earnings per share was 0.63.
Revenue31.38B
Gross Profit22.33B
Operating Income4.02B
Pretax Income3.48B
Net Income2.58B
EBITDA6.67B
Earnings Per Share (EPS)0.63
Cash Flow
In the last 12 months, operating cash flow was 6.29B and capital expenditures -2.98B, giving a free cash flow of 3.32B billion.
Operating Cash Flow6.29B
Free Cash Flow3.32B
Free Cash Flow per Share0.81
Dividends & Yields
GlaxoSmithKline pays an annual dividend of 15.999p, resulting in a dividend yield of 4.39%
Dividend Per Share15.999p
Dividend Yield4.39%
Payout Ratio10.04%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.70
52-Week Price Change-13.43%
50-Day Moving Average1.44K
200-Day Moving Average1.43K
Relative Strength Index (RSI)49.13
Average Volume (3m)11.05M
Important Dates
GlaxoSmithKline upcoming earnings date is Apr 30, 2025, TBA Not Confirmed.
Last Earnings DateFeb 5, 2025
Next Earnings DateApr 30, 2025
Ex-Dividend DateFeb 20, 2025
Financial Position
GlaxoSmithKline as a current ratio of 0.78, with Debt / Equity ratio of 124.25%
Current Ratio0.78
Quick Ratio0.52
Debt to Market Cap0.29
Net Debt to EBITDA―
Interest Coverage Ratio6.28
Taxes
In the past 12 months, GlaxoSmithKline has paid 526.00M in taxes.
Income Tax526.00M
Effective Tax Rate0.15
Enterprise Valuation
GlaxoSmithKline EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
GlaxoSmithKline has £3.71B in cash and marketable securities with £16.99B in debt, giving a net cash position of £13.27B billion.
Cash & Marketable Securities£3.71B
Total Debt£16.99B
Net Cash£13.27B
Net Cash Per Share£3.23
Tangible Book Value Per Share-£2.31
Margins
Gross margin is 71.40%, with operating margin of 12.82%, and net profit margin of 8.21%.
Gross Margin71.40%
Operating Margin12.82%
Pretax Margin11.08%
Net Profit Margin8.21%
EBITDA Margin21.25%
EBIT Margin13.12%
Analyst Forecast
The average price target for GlaxoSmithKline is £1,583.64, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target£1,583.64
Price Target Upside14.01% Upside
Analyst ConsensusHold
Analyst Count11
Revenue Growth Forecast3.46%
EPS Growth Forecast-48.06%